期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Advancing chimeric antigen receptor T cel therapy with CRISPR/Cas9 被引量:9
1
作者 Jiangtao Ren Yangbing Zhao 《Protein & Cell》 SCIE CAS CSCD 2017年第9期634-643,共10页
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Casg) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/ ... The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Casg) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology. CRISPR/ Cas9 has demonstrated great potential for genetic manipulation. In this review, we discuss the current development of CRISPR/Cas9 technologies for thera- peutic applications, especially chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy. Different methods used to facilitate efficient CRISPR delivery and gene editing in T cells are compared. The potential of genetic manipulation using CRISPR/Cas9 system to generate universal CAR T cells and potent T cells that are resistant to exhaustion and inhibition is explored. We also address the safety concerns associated with the use of CRISPR/Cas9 gene editing and provide potential solutions and future directions of CRISPR application in the field of CAR T cell immunotherapy. As an integration-free gene insertion method, CRISPR/Cas9 holds great promise as an efficient gene knock-in platform. Given the tremendous progress that has been made in the past few years, we believe that the CRISPPJ Cas9 technology holds immense promise for advancing immunotherapy. 展开更多
关键词 CRISPR/Cas9 chimeric antigen receptor t lymphocytes adoptive immunotherapy gene therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部